Thermodynamic Protein Biodesign
Stablebody Technologies, LLC Has Created An Elegantly Simple, Yet Incredibly Powerful Method To Solve The Problem Of Incremental Utility Expenses With Cold-Chain Handling.
Introducing The Future Of Protein Engineering
AffiBio-UIA™
AffiBio-UIA™ utilizes a set of unique and proprietary algorithms that are derived from a computer-assisted libraries of amino acid combinations and substitutions. These combinations and substitutions are rearranged systematically, for structurally and functionally improved antibody proteins, that are Cold-Chain Free™.
Cold-Chain logistics is essential to ensure the efficacy and safety of protein products. This requires specialized and expensive refrigeration equipment, temperature monitoring devices and proper handling procedures. The cost of Cold-Chain logistics can be up to 20% of the total cost of the product, which is significant.
“No longer will an antibody fail to reach its full therapeutic and diagnostic potential, due to physical instability or function.”
Dr. Fred Stevens – Co-Founder
Challenges of Antibody Biodesign
Laboratory discovery and development of optimal functioning antibody proteins is a very long, arduous, and an expensive ordeal because.....
Antibody proteins are fragile in ambient conditions
Temperature, chemical, and enzyme degradation at ambient conditions reduced performance over time requiring expensive cold-storage
Antibody protein function is nearly impossible to predict
With lot-to-lot variability in manufacturing causing inconsistent reproducibility issues
AffiBio-UIA™ Algorithms
The Solution to Protein Biodesign Challenges
FACT: Proteins, specifically antibody proteins, have to be refrigerated to maintain their efficacy whether for diagnostic or therapeutic applications.
Currently, there is no known protein amino acid sequence alignment user interface tool known that is available for every-day scientists to solve thermal stability problems leading to improved affinity performance of antibody proteins.
StableBody Technologies, LLC is offering its rational protein design technology as a User Interface Application for scientists everywhere working with amino acid sequence alignment data in protein design and engineering from their lab bench base with built-in automation components for design work.
Our Core Rational Protein Design Method:
AffiBio-UIA™
The Universal Rational Biodesign of Antibody Proteins Using Proprietary Thermodynamic Stabilization Algorithms.
Benefits of Thermodynamic Stabilization:
- Can improve antibody protein binding properties for higher sensitivity and specificity!
- Can improve antibody protein thermodynamic stability to eliminate cold-chain requirements for shipping and storage!
- Can improve antibody protein purification and production yields and timelines!
- Can improve research, development, regulatory and manufacturing timelines!
- Can improve product to market timelines!
Technology Needs
“Cold-Chain” is often the recommended temperature-controlled supply chain, from the point of manufacture to the end-user. Freezers, coolers, warehouse and working room HVAC systems, transportation vehicles, and incremental utility expenses are examples of the cold-chain handling system necessary to assure a product’s efficacy. When any part of the cold-chain continuum lapses, products must be destroyed since performance is risked.
The Biopharma industry using temperature-sensitive drugs, vaccines, diagnostics, and blood products, is enjoying strong growth in product development and expanding market sales. Yet, the industry is confronted with rising cost pressures from payers worldwide. It costs more to keep products at refrigerated or at frozen temperatures than it does to keep them at uncontrolled ambient (room temperature) conditions. There is more to pack and transport them cold, and more to be able to demonstrate by process qualification or by measurement of each shipment that the products stay cold.
Proteins are governed by laws of thermodynamic principles. Using these principles to predict protein structure/function has been neglected in the past because of the vast complexity of thermodynamic properties. These properties have near-infinite conformational possibilities in proteins.
StableBody Technologies, LLC has the SBT Rational Protein Design Method, AffiBio-UIA™, that utilizes a set of unique and proprietary algorithms derived from a computer-assisted libraries of amino acid combinations and substitutions. When these combinations and substitutions are rearranged systematically, AffiBio-UIA™ generates amino acid sequences for structurally and functionally improved antibody proteins, that are Cold-Chain Free™.
The Biopharma industry using temperature-sensitive drugs, vaccines, diagnostics, and blood products, is enjoying strong growth in product development and expanding market sales. Yet, the industry is confronted with rising cost pressures from payers worldwide. It costs more to keep products at refrigerated or at frozen temperatures than it does to keep them at uncontrolled ambient (room temperature) conditions. There is more to pack and transport them cold, and more to be able to demonstrate by process qualification or by measurement of each shipment that the products stay cold.
Proteins are governed by laws of thermodynamic principles. Using these principles to predict protein structure/function has been neglected in the past because of the vast complexity of thermodynamic properties. These properties have near-infinite conformational possibilities in proteins.
StableBody Technologies, LLC has the SBT Rational Protein Design Method, AffiBio-UIA™, that utilizes a set of unique and proprietary algorithms derived from a computer-assisted libraries of amino acid combinations and substitutions. When these combinations and substitutions are rearranged systematically, AffiBio-UIA™ generates amino acid sequences for structurally and functionally improved antibody proteins, that are Cold-Chain Free™.
Leadership Team
H. Rossiter Horn, R.Ph.
Founder, and Chief Executive Officer
Harry has over 25 years of experience in the biotech and pharmaceutical industries, working with both Fortune 50 and start-up companies. He has owned a successful consulting business focused on strategic business, clinical and corporate development, directed a successful strategic clinical development program at SangStat Medical Corporation, was responsible for a multi-million-dollar sales territory with Ortho Biotech, and enjoyed a successful sales career at Knoll Pharmaceuticals. Mr. Horn holds a B.S. (R.Ph.) degree in Pharmacy from the Temple University School of Pharmacy and a B.S. in Biology from the University of Scranton.
Joe Firca, PH.D.
Founder, Chief Scientific Officer
Joe has more than 35 years of extensive operating and product development knowledge and is a recognized leader in the life science and biotechnology arena in matters of research, technology assessment, and regulatory issues. He has a combined 18 years leading research groups at Baxter International and Abbott Laboratories. Throughout his distinguished career, Dr. Firca has contributed to numerous publications and patents. Some of his contributions include co-development of the first automated DNA synthesizer; Abbott liaison to Amgen, Inc. for a joint collaboration on DNA probes for infectious diseases; systems integration for major instrumentation in blood donor screening; and the development of numerous approved immunoassays for the detection of infectious disease agents. Most recently he served as Adjunct Associate Professor in Biomedical Engineering and Associate Director of Corporate Relations at the McCormick School of Engineering, Northwestern University. Dr. Firca holds a Ph.D. in Microbiology (Microbial Genetics) from the University of Cincinnati, an M.S. in Microbiology (Mycology) from Duquesne University and a B.S. in Biology from Xavier University and has done postdoctoral work at Argonne National Laboratory.
Ed Corrigan, PH.D.
Founder, Chairman and Chief Financial Officer
Ed has had extensive financial management, regulatory compliance, and retail and investment banking experience in both the private and public sectors. He is the founder of a successful early stage Food Safety, Human Clinical, and Veterinary Diagnostics biotechnology company that has been in business 15 years. He has overseen a biotechnology laboratory and supervised the development of a hand-held biosensor instrument now on the market. His training is in public finance and economics. Dr. Corrigan holds a B.A degree from Rutgers College, and M.A. (Economics) and Ph.D. (International Economics) degrees from the University of Denver.
Daniel Kaye
Independent Director
Dan has more than 40 years of executive business experience in finance, auditing, governance & risk management, and is a retired Managing Partner – Assurance at Ernst and Young LLP, Chicago where he was responsible for more than 1,600 Assurance professionals in 10 offices across 12 states. Mr. Kaye currently is a member of the Board of Directors for Alliance Bernstein Holdings NYSE (AB), AXE Equitable Holdings NYSE (EQH) and CME Group.
